Brazil · Delayed Price · Currency is BRL Intra-Cellular Therapies Statistics
Total Valuation
Merck & Co. has a market cap or net worth of BRL 1.11 trillion. The enterprise value is 1.25 trillion.
| Market Cap | 1.11T |
| Enterprise Value | 1.25T |
Important Dates
The last earnings date was Tuesday, July 29, 2025.
| Earnings Date | Jul 29, 2025 |
| Ex-Dividend Date | Jun 13, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.77% |
| Shares Change (QoQ) | -0.71% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.51B |
Valuation Ratios
The trailing PE ratio is 12.36 and the forward PE ratio is 8.66.
| PE Ratio | 12.36 |
| Forward PE | 8.66 |
| PS Ratio | 3.19 |
| PB Ratio | 4.19 |
| P/TBV Ratio | 18.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 13.96 |
| EV / Sales | 3.53 |
| EV / EBITDA | 7.62 |
| EV / EBIT | 9.07 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 1.18 |
| Debt / FCF | n/a |
| Interest Coverage | 19.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 18.81% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | 4.68M |
| Profits Per Employee | 1.21M |
| Employee Count | 75,000 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Merck & Co. has paid 14.95 billion in taxes.
| Income Tax | 14.95B |
| Effective Tax Rate | 14.32% |
Stock Price Statistics
The stock price has decreased by -31.72% in the last 52 weeks. The beta is 0.40, so Merck & Co.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -31.72% |
| 50-Day Moving Average | 55.71 |
| 200-Day Moving Average | 65.12 |
| Relative Strength Index (RSI) | 44.82 |
| Average Volume (20 Days) | 6,147 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.91 |
Income Statement
In the last 12 months, Merck & Co. had revenue of BRL 346.63 billion and earned 89.39 billion in profits. Earnings per share was 35.34.
| Revenue | 346.63B |
| Gross Profit | 269.32B |
| Operating Income | 135.03B |
| Pretax Income | 104.42B |
| Net Income | 89.39B |
| EBITDA | 158.87B |
| EBIT | 135.03B |
| Earnings Per Share (EPS) | 35.34 |
Balance Sheet
The company has 50.28 billion in cash and 189.86 billion in debt, giving a net cash position of -139.58 billion.
| Cash & Cash Equivalents | 50.28B |
| Total Debt | 189.86B |
| Net Cash | -139.58B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 263.72B |
| Book Value Per Share | 104.67 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 77.70%, with operating and profit margins of 38.95% and 25.79%.
| Gross Margin | 77.70% |
| Operating Margin | 38.95% |
| Pretax Margin | 30.12% |
| Profit Margin | 25.79% |
| EBITDA Margin | 45.83% |
| EBIT Margin | 38.95% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.56, which amounts to a dividend yield of 2.85%.
| Dividend Per Share | 1.56 |
| Dividend Yield | 2.85% |
| Dividend Growth (YoY) | 18.42% |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | 0.77% |
| Shareholder Yield | 3.62% |
| Earnings Yield | 8.09% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 29, 2020. It was a forward split with a ratio of 8.
| Last Split Date | Oct 29, 2020 |
| Split Type | Forward |
| Split Ratio | 8 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |